EVGNNasdaqAgricultural ChemicalsFiscal year ends December 31
Evogene Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026
$0.37−0.02 (-4.71%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 0.3
- Dividend yield
- –
Evogene Ltd. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- -6.3%
- Operating margin
- -364.2%
- Net margin
- -220.2%
- Return on equity, FY2025
- 1107.0%
Financial strength
- Current ratio
- 3.57
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 306.0%
Valuation
- P/E ratio
- 0.3
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –